| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 2nd June 2020 | Michael Sardano | 1,483 | Payment by withholding | $3.05 | $4,523.15 |
| 2nd June 2020 | Javier Rampolla | 1,186 | Payment by withholding | $3.05 | $3,617.30 |
| 2nd June 2019 | Michael Sardano | 1,948 | Payment by withholding | $5.59 | $10,889.32 |
| 2nd June 2019 | Arthur Levine | 14,628 | Payment by withholding | $5.59 | $81,770.52 |
| 22nd March 2019 | Kalman Fishman | 173 | Open or private sale | $7.50 | $1,297.50 |
| 22nd March 2019 | Stephen Brad Cohen | 595 | Open or private sale | $7.50 | $4,462.50 |
| 22nd March 2019 | Richard Golin | 492 | Open or private sale | $7.50 | $3,690.00 |
| 21st March 2019 | Richard Golin | 509 | Open or private sale | $7.50 | $3,817.50 |
| 20th March 2019 | Richard Golin | 5,943 | Open or private sale | $7.56 | $44,929.08 |
Sensus Healthcare
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Sensus Healthcare's SRT-100 is a photon x-ray low energy superficial radiotherapy system. It provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions.
Ticker: SRTS
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1494891
Employees: 53
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
